<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02560532</url>
  </required_header>
  <id_info>
    <org_study_id>AC-054-203</org_study_id>
    <secondary_id>2015-002721-18</secondary_id>
    <nct_id>NCT02560532</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage</brief_title>
  <acronym>REVERSE</acronym>
  <official_title>A Prospective, Multi-center, Open-label, Single-arm, Phase 2 Study to Assess the Efficacy and Safety of Clazosentan in Reversing Angiographically-confirmed Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) Treated by Surgical Clipping or Endovascular Coiling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and potential therapeutic benefit of use
      of clazosentan in reversing cerebral vasospasm (a narrowing of blood vessels in the brain due
      to the presence of blood in the space around the brain) in patients who have suffered a
      condition known as aneurysmal subarachnoid hemorrhage caused by bleeding onto the surface of
      the brain from a ruptured brain aneurysm
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aneurysmal subarachnoid hemorrhage (aSAH) is characterized by bleeding onto the brain surface
      due to a rupture of a pouch or bulge in a brain vessel (called an aneurysm). It is a rare but
      serious condition with a high risk of death. Even patients who have had successful repair of
      the aneurysm remain at risk for developing cerebral vasospasm, which can result in harmful
      conditions related to the lack of oxygen to parts of the brain and death. Cerebral vasospasm
      usually occurs within the first couple of weeks after aSAH, and it is difficult to treat.
      Currently there is no safe, efficacious and widely available treatment. Previous animal
      studies have shown that a new drug under investigation, clazosentan, was able to reverse
      cerebral vasospasm in animal models of SAH. A first trial conducted in a small number of
      patients showed some benefit of clazosentan in reversing established cerebral vasospasm after
      aSAH. Clazosentan has already been evaluated in the prevention of cerebral vasospasm in
      several large clinical trials in aSAH. This current study aims to evaluate if clazosentan is
      effective and safe in the treatment of cerebral vasospasm after aSAH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1, 2016</start_date>
  <completion_date type="Actual">May 2, 2017</completion_date>
  <primary_completion_date type="Actual">May 2, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful reversal of global cerebral vasospasm 3 hours post-study drug initiation</measure>
    <time_frame>3 hours post-study drug initiation</time_frame>
    <description>Successful reversal is defined as an improvement in at least one level of severity on the &quot;global vasospasm assessment&quot; (i.e., from severe to moderate, mild, or none, or from moderate to mild or none), evaluated on Digital subtraction angiogram (DSA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful reversal of global cerebral vasospasm 24 hours post-study drug initiation</measure>
    <time_frame>24 hours post-study drug initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change from baseline in angiographic cerebral circulation time (CCT)</measure>
    <time_frame>At baseline, 3 hours and 24 hours post-study drug initiation</time_frame>
    <description>CCT will be determined in the left and right anterior circulation, and the posterior circulation, on the digital subtraction angiogram (DSA) at each scheduled time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Up to 30 days after study drug discontinuation</time_frame>
    <description>An adverse event is defined as any unfavorable and unintended sign, including an abnormal laboratory finding, symptom or disease, that occurs during the course of the study, whether or not considered related to the study drug</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Clazosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diluted solution administered as a continuous intravenous infusion at a rate of 15 mg/h for up to a cumulative maximum of 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clazosentan</intervention_name>
    <description>Concentrated solution for intravenous injection</description>
    <arm_group_label>Clazosentan</arm_group_label>
    <other_name>ACT-108475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent from the subject or proxy/legal representative

          -  Aneurysmal subarachnoid hemorrhage (aSAH)confirmed by digital subtraction angiogram
             (DSA) or computed tomography angiogram (CTA), successfully secured by surgical
             clipping or endovascular coiling within 72 hours of rupture

          -  World Federation of Neurological Surgeons (WFNS) grade 1-4 at admission, and which
             must not increase to grade 5 at the time of enrollment

          -  Moderate or severe global cerebral vasospasm at the time of enrollment, documented by
             digital subtraction angiography (DSA) performed not earlier than 48 hours post
             aneurysm-securing procedure

          -  Women of childbearing potential must have a negative serum pregnancy test at screening
             and must use a reliable method of contraception from hospital discharge up to 30 days
             after discontinuation of study drug infusion, and fertile males must use a condom as a
             contraceptive method during this same period

        Exclusion Criteria:

          -  SAH due to causes other than a saccular aneurysm

          -  Any moderate or severe cerebral vasospasm on angiography prior to the
             aneurysm-securing procedure

          -  Presence of a new or worsened cerebral infarct or evidence of significant bleeding
             post aneurysm-securing procedure, or re-bleeding, on a CT scan performed within 24
             hours prior to enrollment

          -  Total bilirubin &gt; 2 times the upper limit of normal, and / or a known diagnosis or
             clinical suspicion of liver cirrhosis or moderate to severe hepatic impairment

          -  Any severe or unstable concomitant condition or disease (e.g., cancer, hematological,
             or coronary disease) or chronic condition (e.g., drug abuse, severe alcoholism),
             which, in the opinion of the investigator, would interfere with the assessment of the
             safety or effect of the study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelina Marr, BSc. Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 2002</name>
      <address>
        <city>Helsinki</city>
        <zip>00260</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1002</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1006</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1004</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1005</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1001</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3005</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3001</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3003</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3004</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3002</name>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aneurysmal subarachnoid hemorrhage</keyword>
  <keyword>cerebral vasospasm</keyword>
  <keyword>clazosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

